Dr. Dhanoa is the CEO of Akaal Pharma. Previously he was the Managing Director and Chairman of the Scientific Advisory Board of Akaal Pharma. Dr. Dhanoa has nearly 20 years of experience in management and directing research and development in drug discovery and development with a proven track record of success. He is a co-inventor and co-author of over 100 patents and publications. He has held positions of increasing responsibilities at Merck, Synaptic Pharmaceuticals, Alanex Corporation, 3-Dimensional Pharmaceuticals, Pharmacore and Predix Pharmaceuticals. He was the founding Senior Vice President of R&D at Predix Pharmaceuticals, and later Senior Vice President of Drug Discovery at Predix Pharmaceuticals Holding Company after M&A of Predix with Physiome Sciences. He was the Executive Vice President and Chief Scientific Officer at PharmaCore, Executive Director of Drug Discovery at 3-Dimensional Pharmaceuticals (dddp/nasdaq, acquired by Johnson & Johnson), Director of Chemistry at Alanex (acquired by Agouron, now Pfizer), Associate Director of Medicinal Chemistry at Synaptic Pharmaceuticals (snap/nasdaq, acquired by H. Lundbeck A/S). Under Dr. Dhanoa’s R&D direction and management at Predix Pharmaceuticals, several new small molecule drug candidates were discovered in an unprecedented short period of less than three years. Four of these novel clinical product candidates advanced through Phase I, II and III clinical trials. PRX-03140, a novel drug candidate for the treatment of Alzheimer’s Disease, was partnered with GlaxoSmithKline(GSK) for $1.2 Billion. The pipeline of new and innovative drug candidates created by Dr. Dhanoa and his team at Predix resulted in raising significant venture capital prior to its M&A with Epix Pharma (epix/nasdaq).
Mr. Sandhu is the chairman, co-founder and the Principal Investor of Akaal Pharma. He is an accomplished investor and entrepreneur with over 30 years experience in starting and financing businesses in various sectors. By capitalizing on his acute business acumen, technical expertise and strategic mind-set, Mr. Sandhu was successful in penetrating new markets and achieving unprecedented growth for his companies. He is dedicated to the success and growth of Akaal Pharma.
Dr. Grobelny is a co-founder and Senior Scientist at Akaal Pharma. He has over 35 years of experience in organic and medicinal chemistry both in a pharma/biotech and academic institutes of Europe, North America and Australia. Dr. Grobelny has authored/invented and co-authored/co-invented over 80 significant publications and patents in organic and medicinal chemistry. Prior to joining Akaal Pharma, he was the Head of Research of Narhex Life Sciences and Head of Medicinal Chemistry of Bionomics Limited.
Dr. Gill is co-founder and VP R&D of Akaal Pharma. He has more than 10 years of experience in medicinal chemistry and drug discovery of novel therapeutics both in academic and industry. He was a post doctoral fellow at the University of Otago, New Zealand and worked on the medicinal chemistry/drug discovery project in immune modulators. Dr. Gill started his carrier in medicinal chemistry with Crystal Genomics Inc. and later he worked on various drug discovery projects at Iliad Chemicals and Bionomics Ltd. He has experience on drug discovery projects related to cancer, immune mediated and central nervous system diseases. Dr. Gill is author and inventor of over 25 patents/applications and publications.
Professor Singh is a Distinguished University Professor, Sherman Financial Group Endowed Chair and Scientific Director of the Darby Children’s Research Institute at Medical University of South Carolina, Charleston. He served as a faculty member at the Johns Hopkins School of Medicine at Baltimore, MD. Professor Singh received his Ph.D. degree from Iowa State University, Ames, Iowa and did postdoctoral fellowship at Massachusetts General Hospital/Harvard Medical School at Boston, MA. Prof. Singh has 35 year of experience in pre-clinical and clinical research related to inflammatory/autoimmune and central nervous system diseases. He has published over 270 research papers in peer reviewed journals and was speaker of international and national scientific conference with over 200 presentations.His research program has been continuously supported by several grants funding from multiple agencies including National Institutes of Health, National Science Foundation, Multiple Sclerosis Society, Spinal Research Foundation and Leukodystrophy Foundation. Based on the scientific achievements, Dr. Singh has received many meritorious awards including Jacob Javits Award from National Institutes of Health given for meritorious research in the field of neuroscience.